first post

We are a clinical stage, specialty pharmaceutical company focused on developing drug candidates for “orphan” oncology indications that potentially address areas of high unmet medical need in the treatment of cancer. Our strategy is to acquire late-stage compounds to pursue a lower cost and accelerated development pathway. By definition, late-stage compounds on average have lower development risk and shorter development timelines compared to early-stage compounds, and thus this strategy is intended to reduce overall clinical development risks and timelines. Additional investment to develop these drug candidates can potentially lead to swifter approval and their clinical application.